Download PDF
Horm Metab Res 2019; 51(03): 191-199
DOI: 10.1055/a-0802-9569
Endocrine Care
© Georg Thieme Verlag KG Stuttgart · New York

Gut Hormone Responses to Mixed Meal Test in New-Onset Prediabetes/Diabetes After Acute Pancreatitis

Sayali A. Pendharkar
1   School of Medicine, University of Auckland, Auckland, New Zealand
,
Ruma G. Singh
1   School of Medicine, University of Auckland, Auckland, New Zealand
,
Aya Cervantes
1   School of Medicine, University of Auckland, Auckland, New Zealand
,
Steve V. DeSouza
1   School of Medicine, University of Auckland, Auckland, New Zealand
,
Sakina H. Bharmal
1   School of Medicine, University of Auckland, Auckland, New Zealand
,
Maxim S. Petrov
1   School of Medicine, University of Auckland, Auckland, New Zealand
› Author Affiliations
Further Information

Publication History

received 22 June 2018

accepted 13 November 2018

Publication Date:
20 December 2018 (online)

Also available at
    Permissions and Reprints

Abstract

The study was aimed to investigate gut hormone responses to mixed meal test in individuals with new-onset prediabetes or diabetes after acute pancreatitis (cases) compared with healthy controls, and the effect of body fat parameters. A total of 29 cases and 29 age- and sex-matched healthy controls were recruited. All participants were given standard mixed meal drink and blood samples were collected to measure dipeptidyl peptidase IV, gastric inhibitory peptide, glucagon like peptide-1, insulin, oxyntomodulin, and peptide YY. Body fat parameters were measured using magnetic resonance imaging. Repeated measures and linear regression analyses were conducted in unadjusted and adjusted models. Gastric inhibitory peptide levels were significantly higher whereas oxyntomodulin levels were significantly lower in cases compared with controls in both the unadjusted (p<0.001 and p<0.001, respectively) and adjusted (p<0.001 and p<0.001, respectively) models. In cases, liver fat % contributed up to 13.4% (vs. 2.9% in controls) to variance in circulating levels of gastric inhibitory peptide whereas body mass index - up to 20.8% (vs. 9.9% in controls) in circulating levels of oxyntomodulin. New-onset prediabetes/diabetes after acute pancreatitis is characterised by increased levels of gastric inhibitory peptide and decreased levels of oxyntomodulin. Further, liver fat % and body mass index appear to be the body fat parameters that contribute most significantly to gastric inhibitory peptide and oxyntomodulin levels, respectively.

Key words

body mass index - gastric inhibitory peptide - glucagon like peptide-1 - liver fat - new-onset diabetes after acute pancreatitis - oxyntomodulin

Supplementary Material

 

  • References

  • 1 Tuomi T, Santoro N, Caprio S, Cai M, Weng J, Groop L. The many faces of diabetes: A disease with increasing heterogeneity. Lancet 2014; 383: 1084-1094
    CrossrefPubMedSearch in Google Scholar
  • 2 Jivanji CJ, Asrani VM, Windsor JA, Petrov MS. New onset diabetes after acute and critical illness: a systematic review. Mayo Clin Proc 2017; 92: 762-773
    CrossrefPubMedSearch in Google Scholar
  • 3 Petrov MS. Diabetes of the exocrine pancreas: American Diabetes Association-compliant lexicon. Pancreatology 2017; 523-526
    PubMedSearch in Google Scholar
  • 4 Woodmansey C, McGovern AP, McCullough KA, Whyte MB, Munro NM, Correa AC, Gatenby PAC, Jones SA, de Lusignan S. Incidence, demographics, and clinical characteristics of diabetes of the exocrine pancreas (type 3c): A retrospective cohort study. Diabetes Care 2017; 40: 1486-1493
    CrossrefPubMedSearch in Google Scholar
  • 5 Petrov MS, Yadav D. Global epidemiology and holistic prevention of pancreatitis. Nat Rev Gastroenterol Hepatol 2018 [Epub ahead of print]
    PubMed
  • 6 Xiao AY, Tan ML, Wu LM, Asrani VM, Windsor JA, Yadav D, Petrov MS. Global incidence and mortality of pancreatic diseases: A systematic review, meta-analysis, and meta-regression of population-based cohort studies. Lancet Gastroenterol Hepatol 2016; 1: 45-55
    Search in Google Scholar
  • 7 Pendharkar SA, Mathew J, Zhao J, Windsor JA, Exeter DJ, Petrov MS. Ethnic and geographic variations in the incidence of pancreatitis and post-pancreatitis diabetes mellitus in New Zealand: A nationwide population-based study. NZ Med J 2017; 130: 55-68
    PubMedSearch in Google Scholar
  • 8 Das SL, Singh PP, Phillips AR, Murphy R, Windsor JA, Petrov MS. Newly diagnosed diabetes mellitus after acute pancreatitis: A systematic review and meta-analysis. Gut 2014; 63: 818-831
    CrossrefPubMedSearch in Google Scholar
  • 9 Meier JJ, Nauck MA. Incretin-based therapies: where will we be 50 years from now?. Diabetologia 2015; 58: 1745-1750
    CrossrefPubMedSearch in Google Scholar
  • 10 Latorre R, Sternini C, De Giorgio R, Greenwood-Van Meerveld B. Enteroendocrine cells: A review of their role in brain-gut communication. Neurogastroenterol Motil 2016; 28: 620-630
    CrossrefPubMedSearch in Google Scholar
  • 11 Singh RG, Yoon HD, Wu LM, Lu J, Plank LD, Petrov MS. Ectopic fat accumulation in the pancreas and its clinical relevance: A systematic review, meta-analysis, and meta-regression. Metabolism 2017; 69: 1-13
    CrossrefPubMedSearch in Google Scholar
  • 12 Singh RG, Yoon HD, Poppitt SD, Plank LD, Petrov MS. Ectopic fat accumulation in the pancreas and its biomarkers: a systematic review and meta-analysis. Diabetes Metab Res Rev 2017; 33: e2918
    CrossrefPubMedSearch in Google Scholar
  • 13 Knop FK, Vilsbøll T, Højberg PV, Larsen S, Madsbad S, Holst JJ, Krarup T. The insulinotropic effect of GIP is impaired in patients with chronic pancreatitis and secondary diabetes mellitus as compared to patients with chronic pancreatitis and normal glucose tolerance. Regul Pept 2007; 144: 123-130
    CrossrefPubMedSearch in Google Scholar
  • 14 Maraví Poma E, Laplaza Santos C, Gorraiz López B, Albeniz Arbizu E, Zubia Olascoaga F, Petrov MS, Morales FA, Aizcorbe Garralda M, Casi Villaroya M, Sánchez-Izquierdo Riera JA, López Camps V, Regidor Sanz E, Loinaz Bordonabe M, do Pico JL. Grupo Hoja de Ruta de la PAG en Intensivos, Scientific Committee of the SEMICYUC, Working Group on Infectious Diseases (GTEI-SEMICYUC). [Clinical pathways in acute pancreatitis: recommendations for early multidisciplinary management. Scientific Committee of the SEMICYUC. Working Group on Infectious Diseases (GTEI-SEMICYUC)]. Med Intensiva 2012; 36: 351-357
    CrossrefPubMedSearch in Google Scholar
  • 15 Stigliano S, Sternby H, de Madaria E, Capurso G, Petrov MS. Early management of acute pancreatitis: A review of the best evidence. Dig Liver Dis 2017; 49: 585-594
    CrossrefPubMedSearch in Google Scholar
  • 16 American Diabetes Association. Classification and diagnosis of diabetes: Standards of medical care in diabetes-2018. Diabetes Care 2018; 41: S13-S27
    CrossrefPubMedSearch in Google Scholar
  • 17 Singh RG, Nguyen NN, DeSouza SV, Pendharkar SA, Petrov MS. Comprehensive analysis of body composition and insulin traits associated with intra-pancreatic fat deposition in healthy individuals and people with new-onset prediabetes/diabetes after acute pancreatitis. Diabetes Obes Metab 2018; [Epub ahead of print]
    CrossrefPubMedSearch in Google Scholar
  • 18 Pendharkar SA, Singh RG, Bharmal SH, Drury M, Petrov MS. Pancreatic hormone responses to mixed meal test in new-onset prediabetes/diabetes after non-necrotizing acute pancreatitis. J Clin Gastroenterol 2018 [Epub ahead of print]
    PubMed
  • 19 Petrov MS. The nescience and nascence of gastrointestinal motility research in acute pancreatitis. Scand J Gastroenterol 2017; 52: 615-616
    CrossrefPubMedSearch in Google Scholar
  • 20 Wynne K, Park AJ, Small CJ, Patterson M, Ellis SM, Murphy KG, Wren AM, Frost GS, Meeran K, Ghatei MA, Bloom SR. Subcutaneous oxyntomodulin reduces body weight in overweight and obese subjects: A double-blind, randomized, controlled trial. Diabetes 2005; 54: 2390-2395
    CrossrefPubMedSearch in Google Scholar
  • 21 Nauck MA, Baller B, Meier JJ. Gastric inhibitory polypeptide and glucagon-like peptide-1 in the pathogenesis of type 2 diabetes. Diabetes 2004; 53 (Suppl. 03) S190-S196
    PubMedSearch in Google Scholar
  • 22 Meier JJ, Nauck MA. Is the diminished incretin effect in type 2 diabetes just an epi-phenomenon of impaired beta-cell function?. Diabetes 2010; 59: 1117-1125
    CrossrefPubMedSearch in Google Scholar
  • 23 Nauck MA, Homberger E, Siegel EG, Allen RC, Eaton RP, Ebert R, Creutzfeldt W. Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J Clin Endocrinol Metab 1986; 63: 492-498
    CrossrefPubMedSearch in Google Scholar
  • 24 Nauck MA, Vardarli I, Deacon CF, Holst JJ, Meier JJ. Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: What is up, what is down?. Diabetologia 2011; 54: 10-18
    CrossrefPubMedSearch in Google Scholar
  • 25 Ryskjaer J, Deacon CF, Carr RD, Krarup T, Madsbad S, Holst J, Vilsbøll T. Plasma dipeptidyl peptidase-IV activity in patients with type-2 diabetes mellitus correlates positively with HbAlc levels, but is not acutely affected by food intake. Eur J Endocrinol 2006; 155: 485-493
    CrossrefPubMedSearch in Google Scholar
  • 26 Pala L, Ciani S, Dicembrini I, Bardini G, Cresci B, Pezzatini A, Giannini S, Mannucci E, Rotella CM. Relationship between GLP-1 levels and dipeptidyl peptidase-4 activity in different glucose tolerance conditions. Diabet Med 2010; 27: 691-695
    CrossrefPubMedSearch in Google Scholar
  • 27 Pocai A. Unraveling oxyntomodulin, GLP1’s enigmatic brother. J Endocrinol 2012; 215: 335-346
    CrossrefPubMedSearch in Google Scholar
  • 28 Lee AY, Chappell DL, Bak MJ, Judo M, Liang L, Churakova T, Ayanoglu G, Castro-Perez J, Zhou H, Previs S, Souza SC, Lassman ME, Laterza OF. Multiplexed quantification of proglucagon-derived peptides by immunoaffinity enrichment and tandem mass spectrometry after a meal tolerance test. Clin Chem 2016; 62: 227-235
    CrossrefPubMedSearch in Google Scholar
  • 29 Wu Q, Xiao Z, Cheng Z, Tian H. Changes of blood glucose and gastrointestinal hormones 4 months after Roux-en-Y gastric bypass surgery in Chinese obese type 2 diabetes patients with lower body mass index. J Diabetes Investig 2013; 4: 214-221
    CrossrefPubMedSearch in Google Scholar
  • 30 Panaro BL, Tough IR, Engelstoft MS, Matthews RT, Digby GJ, Møller CL, Svendsen B, Gribble F, Reimann F, Holst JJ, Holst B, Schwartz TW, Cox HM, Cone RD. The melanocortin-4 receptor is expressed in enteroendocrine L cells and regulates the release of peptide YY and glucagon-like peptide 1 in vivo. Cell Metab 2014; 20: 1018-1029
    CrossrefPubMedSearch in Google Scholar
  • 31 Pendharkar SA, Drury M, Walia M, Korc M, Petrov MS. Gastrin-releasing peptide and glucose metabolism following pancreatitis. Gastroenterol Res 2017; 10: 224-234
    CrossrefPubMedSearch in Google Scholar
  • 32 Pendharkar SA, Asrani VM, Murphy R, Cutfield R, Windsor JA, Petrov MS. The role of gut-brain axis in regulating glucose metabolism after acute pancreatitis. Clin Transl Gastroenterol 2017; 8: e210
    CrossrefPubMedSearch in Google Scholar
  • 33 Pendharkar SA, Walia M, Drury M, Petrov MS. Calcitonin gene-related peptide: neuroendocrine communication between the pancreas, gut, and brain in regulation of blood glucose. Ann Transl Med 2017; 5: 419
    CrossrefPubMedSearch in Google Scholar
  • 34 Mikada A, Narita T, Yokoyama H, Yamashita R, Horikawa Y, Tsukiyama K, Yamada Y. Effects of miglitol, sitagliptin, and initial combination therapy with both on plasma incretin responses to a mixed meal and visceral fat in over-weight Japanese patients with type 2 diabetes - the MASTER randomized, controlled trial. Diabetes Res Clin Pract 2014; 106: 538-547
    CrossrefPubMedSearch in Google Scholar
  • 35 Singh RG, Pendharkar SA, Gillies NA, Miranda-Soberanis V, Plank LD, Petrov MS. Associations between circulating levels of adipocytokines and abdominal adiposity in patients after acute pancreatitis. Clin Exp Med 2017; 17: 477-487
    CrossrefPubMedSearch in Google Scholar
  • 36 Singh RG, Pendharkar SA, Plank LD, Petrov MS. Role of human lipocalin proteins in abdominal obesity after acute pancreatitis. Peptides 2017; 91: 1-7
    CrossrefPubMedSearch in Google Scholar
  • 37 Singh RG, Pendharkar SA, Cervantes A, Cho J, Miranda-Soberanis V, Petrov MS. Abdominal obesity and insulin resistance after an episode of acute pancreatitis. Dig Liver Dis 2018; 50: 1081-1087
    CrossrefPubMedSearch in Google Scholar
  • 38 Pendharkar SA, Singh RG, Chand SK, Cervantes A, Petrov MS. Pro-inflammatory cytokines after an episode of acute pancreatitis: Associations with fasting gut hormone profile. Inflamm Res 2018; 67: 339-350
    CrossrefPubMedSearch in Google Scholar
  • 39 Pendharkar SA, Singh RG, Petrov MS. Pro-inflammatory cytokine-induced lipolysis after an episode of acute pancreatitis. Arch Physiol Biochem 2018; 124: 401-409
    CrossrefPubMedSearch in Google Scholar
  • 40 Gold-Smith FD, Chand SK, Petrov MS. Post-pancreatitis diabetes mellitus and gastroparesis: Towards understanding the role of gastrointestinal motility.. Minerva Gastroenterol Dietol 2018; 64: 363-375
    PubMedSearch in Google Scholar
  • 41 Pasricha PJ, Camilleri M, Hasler WL, Parkman HP. White Paper AGA: Gastroparesis: clinical and regulatory insights for clinical trials. Clin Gastroenterol Hepatol 2017; 15: 1184-1190
    CrossrefPubMedSearch in Google Scholar
  • 42 Sanger GJ, Lee K. Hormones of the gut-brain axis as targets for the treatment of upper gastrointestinal disorders. Nat Rev Drug Discov 2008; 7: 241-254
    CrossrefPubMedSearch in Google Scholar
  • 43 Kang ES, Yun YS, Park SW, Kim HJ, Ahn CW, Song YD, Cha BS, Lim SK, Kim KR, Lee HC. Limitation of the validity of the homeostasis model assessment as an index of insulin resistance in Korea. Metabolism 2005; 54: 206-211
    CrossrefPubMedSearch in Google Scholar
  • 44 Kanauchi M, Tsujimoto N, Hashimoto T. Validation of simple indices to assess insulin sensitivity based on the oral glucose tolerance test in the Japanese population. Diabetes Res Clin Pract 2002; 55: 229-235
    CrossrefPubMedSearch in Google Scholar
  • 45 Okura T, Nakamura R, Fujioka Y, Kawamoto-Kitao S, Ito Y, Matsumoto K, Shoji K, Sumi K, Matsuzawa K, Izawa S, Ueta E, Kato M, Imamura T, Taniguchi S, Yamamoto K. CPR-IR is an insulin resistance index that is minimally affected by hepatic insulin clearance - A preliminary research. Plos One 2018; 13: e0197663
    CrossrefPubMedSearch in Google Scholar